Surgery versus infliximab for Crohn's disease: should there be a change in clinical practice?

Affiliations

Comment

Naila Arebi. Lancet Gastroenterol Hepatol. 2020 Oct.

. 2020 Oct;5(10):877-878.

doi: 10.1016/S2468-1253(20)30234-X. Epub 2020 Jun 30.

¹ Department of Inflammatory Bowel Diseases, St Mark's Hospital, Imperial College, London HA1 3UJ, UK. Electronic address: naila.arebi@imperial.ac.uk.

No abstract available

Comment on

Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial.
Stevens TW, Haasnoot ML, D'Haens GR, Buskens CJ, de Groof EJ, Eshuis EJ, Gardenbroek TJ, Mol B, Stokkers PCF, Bemelman WA, Ponsioen CY; LIR!C study group. Stevens TW, et al. Lancet Gastroenterol Hepatol. 2020 Oct;5(10):900-907. doi: 10.1016/S2468-1253(20)30117-5. Epub 2020 Jun 30. Lancet Gastroenterol Hepatol. 2020. PMID: 32619413 Clinical Trial.